Hypertensive nephropathy evolution in patients with metabolic syndrome


Cite item

Full Text

Abstract

Aim. Evaluation of course of hypertensive nephropathy in patients with metabolic syndrome.
Methods. 330 patients (303 male, 27 female) with arterial hypertension and no history of chronic kidney disease were included into the study. All patients were divided into 2 groups according to presence or absence of metabolic syndrome. In all patients routine biochemical blood tests, echocardiography and 24-hour blood pressure monitoring were performed. Hypertensive nephropathy was diagnosed, if persistent microalbuminuria (>15 mg/24 hours) was revealed.
Results. Metabolic syndrome was diagnosed in 63,6% of patients with arterial hypertension, its prevalence increased wit age. In 31,4% patients wit metabolisc syndrome microalbuminuria was found more often. Prevalence of hypertensive nephropathy was 35,2% in patients with metabolic syndrome, 16,7% - in patients without metabolic syndrome. In patients with metabolic syndrome signs of hypertensive nephropathy appeared in earlier age.
Conclusion. Metabolic syndrome predisposes to hypertensive nephropathy development in patients with arterial hypertension

References

  1. Комитет экспертов ВНОК. Рекомендации по диагностике и лечению метаболического синдрома. Второй пересмотр. М., 2009.
  2. The IDF consensus worldwide definition of the metabolic syndrome. www.idf.org
  3. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
  4. Grundy S.M., Cleeman J.I., Daniels S.R., et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
  5. Alberti K.G., Zimmet P., Shaw J. Metabolic syndrome - a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 2006; 23: 469-480.
  6. Kahn R., Buse J., Ferrannini E., et al. The Metabolic Syndrome: Time for a Critical Appraisal. Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005; 28 ( 9): 2289-2304.
  7. Wicek A., Kokot F., Chudek J. et al. The adipose tissue - a novel endocrine organ of interest to the nephrologist. Nephrol. Dial. Transplant. 2002; 17:191-195.
  8. Cozma A., Orăşan O., Sâmpelean D., et al. Endothelial dysfunction in metabolic syndrome. Rom. J. Intern. Med. 2009;47(2):133-140.
  9. Крячкова А.А., Савельева С.А., Галлямов М.Г., и соавт. Роль ожирения в поражении почек при метаболическом синдроме. Нефрология и диализ. 2010; Т12. №1: 34-38.
  10. Liu J., Yang J., Sun N.L. Association of microalbuminuria and von Willebrand factor with metabolic syndrome in hypertensive patients. Beijing Da Xue Xue Bao. 2007;39(6):587-590.
  11. Tamba S., Nakatsuji H., Kishida K., et al. Relationship between visceral fat accumulation and urinary albumin-creatinine ratio in middle-aged Japanese men. Atherosclerosis. 2010; 59(4):408-14.
  12. Solbu M.D., Jenssen T.G., Eriksen B.O., et al. Changes in insulin sensitivity, renal function, and markers of endothelial dysfunction in hypertension--the impact of microalbuminuria: a 13-year follow-up study. Metabolism. 2009;58(3):408-415.
  13. Cuspidi C., Valerio C., Giudici V., et al. Metabolic syndrome and multiple organ damage in essential hypertension. Blood Press. 2008; 17(4):195-203.
  14. Vendrell J., Broch M., Vilarrasa N. et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes. Res. 2004; 12(6): 962-971.
  15. Cottone S., Lorito M.C., Riccobene R., et al. Oxidative stress, inflammation and cardiovascular disease in chronic renal failure. J Nephrol. 2008;21(2):175-179.
  16. Tziomalos K., Athyros V.G., Karagiannis A., et al. Endothelial dysfunction in metabolic syndrome: prevalence, pathogenesis and management. Nutr. Metab. Cardiovasc. Dis. 2010;20(2):140-146.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies